Clinical trials: GLP - 1
Transfusion Dependent Beta Thalassemia
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia
Blood transfusion and iron-chelation therapy have prolonged and improved the quality of life in patients with β-thalassemia. The improvement was mainly due to the decrease in mortality from heart failure Such a treatment…
- Trial name
- NCT07370922
- Testing
- Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Congenital Hyperinsulinism
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism (CHI) who have failed medical therapy.
- Trial name
- NCT00835328
- Testing
- Exendin (9-39), Vehicle
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diva De Leon
Insulinoma, Nesidioblastosis
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients.
- Trial name
- NCT02560376
- Testing
- 68Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Postprandial Hypoglycemia
Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
It has been proposed that the rapid gastric emptying of carbohydrate containing fluids into the intestine causes hyperglycemia followed by reactive hypoglycemia.
- Trial name
- NCT01162499
- Testing
- Exendin-(9-39), Vehicle
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Diva De Leon
Obesity
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies.
- Trial name
- BS-GLP (NCT07732738)
- Testing
- BS-GLP1RA group, BS group
- Where
- 7 sites in China
- Volunteers
- 400 people
- Sponsor
- China-Japan Friendship Hospital
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities.
- Trial name
- NCT07169136
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Type 1 Diabetes
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus
To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.
- Trial name
- NCT01235819
- Testing
- Insulin, Sitagliptin, Exenatide
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Command Hospital, India
Gastric Retention
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention
A retrospective observational study to explore the impact of discontinuing GLP-1 receptor agonists for two weeks prior to upper endoscopy on the risk of gastric retention
- Trial name
- NCT07276763
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 16,509 people
- Sponsor
- Fudan University
Type2 Diabetes, Diabetes Mellitus
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D
- Trial name
- SURPASS-PEDS (NCT05260021)
- Testing
- Tirzepatide Dose 1, Tirzepatide Dose 2
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 99 people
- Sponsor
- Eli Lilly and Company
Gestational Diabetes Mellitus
Study of Postprandial Incretin Response in Women With Gestational Diabetes
The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent…
- Trial name
- NCT01274052
- Testing
- Meal test
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type I Diabetes Mellitus
Glutamine and Insulin Sensitivity in Type I Diabetes
Insulin is crucial to help the body metabolize ('burn') sugar (glucose). Even though juvenile (type 1) diabetes (T1D) is primarily due to the lack of insulin, patients with T1D tend to become less sensitive to insulin…
- Trial name
- NCT01467063
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nemours Children's Clinic
Congenital Hyperinsulinism
GLP-1 Receptor Expression in CHI
The primary objective is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of CHI patients.
- Trial name
- GLP-1-CHI (NCT03768518)
- Testing
- 68Ga-exendin-4 PET/CT
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Obesity/Therapy
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults.
- Trial name
- PLASTIC (NCT07021937)
- Testing
- Semaglutide 1.7mg subcutaneous
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
Adolescent Obesity
Antrum Size, Glucagon-like Peptide 1 Levels and Glycemic Control After Sleeve Gastrectomy in Morbid Obese Diabetic Adolescents
Childhood obesity can adversely affect every organ and often has serious consequences. Compare the effect of transection at 2cm vs at 5cm from the pylorus during laparoscopic sleeve gastrectomy on the postoperative weight loss…
- Trial name
- NCT04388059
- Testing
- Laparoscopic sleeve gastrectomy
- Volunteers
- 18 people
- Sponsor
- Tanta University
Hypothalamic Obesity
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind…
- Trial name
- ECHO (NCT02664441)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Seattle Children's Hospital
Wolfram Syndrome
Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1
Wolfram syndrome (WFS:OMIM 222300) is a group of inherited disorders that usually appear in childhood and cause diabetes, optic atrophy leading to loss of vision, deafness and often diabetes insipidus.
- Trial name
- NCT05659368
- Testing
- Tirzepatide
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Ospedale San Raffaele
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying
GLP_1 RA Ultrasound Study
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes
- Trial name
- NCT06581120
- Testing
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Obesity in Children, Bone Strength
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those…
- Conditions
- Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification
- Trial name
- NCT06903923
- Testing
- GLP-1 receptor agonist, Lifestyle intervention
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Virginia
Obese Adolescents, Obesity
A Study of XW003 Injection in Chinese Adolescents With Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity
- Trial name
- NCT07143227
- Testing
- XW003 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Menstrual Irregularities, Type1 Diabetes Mellitus
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
The aim of this study is to measure the frequency of menstrual irregularities among adolescent females with Type 1 diabetes mellitus and to assess the therapeutic effect of glucagon-like peptide-1 receptor agonist on menstrual…
- Conditions
- Menstrual Irregularities, Type1 Diabetes Mellitus, Glucagon-Like Peptide-1 Receptor Agonists, Female Reproductive Health
- Trial name
- NCT07319286
- Testing
- Dulaglutide
- Where
- 2 sites in Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University